首页> 外文期刊>Expert opinion on biological therapy >The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage.
【24h】

The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage.

机译:重组活化因子VII(rFVIIa)在治疗钝性外伤性出血中的新兴作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Recombinant activated Factor VII (rFVIIa; eptacog alpha [activated], NovoSeven) is currently used for the management of a subgroup of haemophilia patients with inhibitors to Factors VIII or IX, and is under investigation as an adjuvant therapy for critical bleeding from other causes, including trauma. rFVIIa has a mode of action founded on physiological coagulation processes, and causes localised haemostasis at injury sites, both spontaneous and traumatic, with the capacity to correct the systemic coagulopathy associated with massive blood loss and its management. This review charts the development of rFVIIa as a new and potent adjuvant therapy for severe bleeding and coagulopathy caused by blunt trauma, where it is reported to produce rapid and significant haemostasis, reducing transfusion requirements and improving clinical outcome.
机译:重组激活的凝血因子VII(rFVIIa; eptacog alpha [activated],NovoSeven)目前用于管理具有凝血因子VIII或IX抑制剂的血友病患者亚组,目前正在研究作为其他原因引起的严重出血的辅助治疗,包括创伤。 rFVIIa具有基于生理凝固过程的作用方式,可在自发性和创伤性损伤部位引起局部止血,并具有纠正与大量失血有关的全身性凝血病及其治疗的能力。这篇综述阐明了rFVIIa作为一种新的有效辅助疗法的发展,该疗法可用于治疗由钝性创伤引起的严重出血和凝血病,据报道该药物可产生快速且显着的止血效果,减少输血需求并改善临床疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号